Abogen announces licensing and option agreement with Novartis

NVS•2026-10-02

Abogen announced a licensing and option agreement with Novartis to advance an mRNA-encoded T-cell engager and other potential RNA programs. Abogen will receive $575 million upfront and is eligible for up to approximately $7.2 billion in potential milestone payments.

Abogen announces licensing and option agreement with Novartis

1. Agreement terms

Related News

3D Investment Partners cuts stake in MediciNova to 9.88% from 11.22%

Raymond James cuts SEI Investments target price to $121 from $124

Wheat heads for fifth weekly fall as traders hope for demand

Regeneron Pharmaceuticals: Jefferies raises target price to $930 from $870

SentinelOne: TD Cowen raises target price to $29 from $26